Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233441 · ClinicalTrials.gov registry record · Phase 2
Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter
A Phase 2 study of Atrial Fibrillation and Atrial Flutter, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 673
- Enrollment target
- 17
- Study locations
NCT00233441: Completed Phase 2 study of Atrial Fibrillation and Atrial Flutter, sponsored by Sanofi.
NCT00233441 is a Phase 2 study of Atrial Fibrillation and Atrial Flutter that has completed, run by Sanofi. The registered enrollment target is 673 participants, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (78% lower). The trial reports 17 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00233441, a Phase 2 study of Atrial Fibrillation and Atrial Flutter, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 673 participants
- Enrollment target
- 17
- Study locations
Study Summary
Double blind study to evaluate the efficacy and tolerability of SSR149744C and select a dose to be further investigated in the maintenance of sinus rhythm after electrical, pharmacological or spontaneous conversion of AF/AFL.
Conditions Studied
Interventions
- DRUG CELIVARONE (SSR149744C)
Study Locations (17)
Other
- Sanofi-Aventis Administrative Office - Buenos Aires
- Sanofi-Aventis Administrative Office - Laval
- Sanofi-Aventis Administrative Office - Santiago
- Sanofi-Aventis Administrative Office - Hørsholm
- Sanofi-Aventis Administrative Office - Paris
- Sanofi-Aventis Administrative Office - Berlin
- Sanofi-Aventis Administrative Office - Budapest
- Sanofi-Aventis Administrative Office - Milan
- Sanofi-Aventis Administrative Office - Tokyo
- Sanofi-Aventis Administrative Office - Gouda
- Sanofi-Aventis Administrative Office - Warsaw
- Sanofi-Aventis Administrative Office - Moscow
- Sanofi-Aventis Administrative Office - Barcelona
- Sanofi-Aventis Administrative Office - Bromma
- Sanofi-Aventis Administrative Office - Geneva
New Jersey
- Sanofi-Aventis Administrative Office - Bridgewater
New South Wales
- sanofi-aventis Australia & New Zealand administrative office - Macquarie Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 673 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
What the finished NCT00233441 record still lists
NCT00233441 is an interventional study that assigns participants to a tested intervention. The registered 673 participants enrollment target is mid-sized for trials with a published cap, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which CELIVARONE (SSR149744C) is the first listed.
NCT00233441 lists 17 locations in 3 states (Other, New Jersey, New South Wales).
Frequently Asked Questions
What is clinical trial NCT00233441 about?
NCT00233441 is a clinical study titled "Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter". Double blind study to evaluate the efficacy and tolerability of SSR149744C and select a dose to be further investigated in the maintenance of sinus rhythm after electrical, pharmacological or spontaneous conversion of AF/AFL.
What is the current status of trial NCT00233441?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 673 participants. The study started on 2004-12. Estimated completion is 2006-05.
What conditions does trial NCT00233441 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Atrial Flutter.
What interventions are being tested in trial NCT00233441?
The interventions under investigation include: CELIVARONE (SSR149744C) (DRUG).
Who is sponsoring clinical trial NCT00233441?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00233441 being conducted?
This trial has 17 study locations across New Jersey, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00233441's enrollment target sits among peer trials
673 45th of 202 higher than 158 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
RECRUITING · Phase 2
-
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
RECRUITING · Phase 2
-
ECG Validation Study
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06335381 · 674 participants · NA
MOMs Chat and Care Study
- NCT06757634 · 674 participants · Phase 3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- NCT05452031 · 672 participants · NA
A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers
- NCT05493254 · 672 participants · NA
Enhancing Smoking Cessation Via Telehealth Options in Primary Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia